Exisulind
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout Exisulind
Exisulind is a phase 1/2 stage product being developed by Astellas Pharma for NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT00072618. Target conditions include NSCLC.
What happened to similar drugs?
7 of 20 similar drugs in NSCLC were approved
Approved (7) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00072618 | Phase 1/2 | Completed |
| NCT00085826 | Phase 3 | Completed |
Competing Products
20 competing products in NSCLC